Weight ManagementAppetiteGlucose / InsulinFat LossBody Composition

Triple receptor agonist · investigational

Retatrutide

Retatrutide is an investigational triple-hormone-receptor agonist with human clinical-trial data. Its regulatory and development status is date-stamped and source-linked below.

FEMETRIC RECORD · PUBLICRetatrutide

Weight ManagementAppetiteGlucose / Insulin

Status: Clinical Development
Related: 2
Sources: 6

UPDATED 2026-09-09

CLINICAL DEVELOPMENT

Retatrutide

Investigational · not approved by any regulatory agency

CURRENT PHASEPhase 3 programSource

LATEST MAJOR RESULTFive positive Phase 3 studies disclosed2026-07-23 · sponsor-reportedSource

NEXT KNOWN MILESTONESponsor-planned FDA submission2027-Q1Source

LAST UPDATED2026-09-09Status source

Published study protocols

Phase 2 · NCT04881760

Retatrutide for obesity — Phase 2

338 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes

Design: 48-week randomized, double-blind, placebo-controlled trial conducted in the United States
Sponsor: Eli Lilly and Company
Duration: 48 weeks

STUDY-BASEDPHASE 2HUMANSOURCE-LINKED

1 mg arm

1 mg fixed weekly

Published fixed-dose arm from the 48-week Phase 2 obesity trial.

Route: Subcutaneous
Frequency: Once weekly
Duration: 48 weeks
Escalation: No escalation

STAGEWEEKSSTUDY DOSE

11–481 mg · 1×/wk

PUBLISHED STUDYJastreboff et al., NEJM 2023Verified 2026-09-09

View primary source

STUDY-BASEDPHASE 2HUMANSOURCE-LINKED

4 mg arms

4 mg target · 2 mg initial

Published 4 mg target arm beginning at 2 mg, with escalation at a four-week interval.

Route: Subcutaneous
Frequency: Once weekly
Duration: 48 weeks
Escalation: Escalated after the first four-week interval

STAGEWEEKSSTUDY DOSE

11–42 mg · 1×/wk

25–484 mg · 1×/wk

PUBLISHED STUDYJastreboff et al., NEJM 2023Verified 2026-09-09

View primary source

STUDY-BASEDPHASE 2HUMANSOURCE-LINKED

4 mg arms

4 mg fixed weekly

Published 4 mg arm that began at the target dose.

Route: Subcutaneous
Frequency: Once weekly
Duration: 48 weeks
Escalation: No escalation

STAGEWEEKSSTUDY DOSE

11–484 mg · 1×/wk

PUBLISHED STUDYJastreboff et al., NEJM 2023Verified 2026-09-09

View primary source

STUDY-BASEDPHASE 2HUMANSOURCE-LINKED

8 mg arms

8 mg target · 2 mg initial

Published 8 mg target arm beginning at 2 mg. Exact intermediate stages are pending direct source extraction.

Route: Subcutaneous
Frequency: Once weekly
Duration: 48 weeks
Escalation: Four-week intervals; intermediate stages pending source extraction

Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.

PUBLISHED STUDYJastreboff et al., NEJM 2023Verified 2026-09-09

View primary source

STUDY-BASEDPHASE 2HUMANSOURCE-LINKED

8 mg arms

8 mg target · 4 mg initial

Published 8 mg target arm beginning at 4 mg. Exact intermediate stages are pending direct source extraction.

Route: Subcutaneous
Frequency: Once weekly
Duration: 48 weeks
Escalation: Four-week intervals; intermediate stages pending source extraction

Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.

PUBLISHED STUDYJastreboff et al., NEJM 2023Verified 2026-09-09

View primary source

STUDY-BASEDPHASE 2HUMANSOURCE-LINKED

12 mg arm

12 mg target · 2 mg initial

Published 12 mg target arm beginning at 2 mg. Exact intermediate stages are pending direct source extraction.

Route: Subcutaneous
Frequency: Once weekly
Duration: 48 weeks
Escalation: Four-week intervals; intermediate stages pending source extraction

Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.

PUBLISHED STUDYJastreboff et al., NEJM 2023Verified 2026-09-09

View primary source

Supply / calculator inputs

01 · STUDY SOURCE1 mg fixed weeklyJastreboff et al., NEJM 2023SOURCE-LINKED

02 · PREPARATION INPUTCustom supply inputEditable planning input — not study dataPENDING VERIFICATION

03 · DERIVED ESTIMATE5 vials48 mg across 48 weeks

Preparation recordVial amount

Reconstitution volume

Published study durationweeks

48 mgPeptide total

5Research vials

10 mLBAC water

48Administrations

Study dose data and preparation inputs are separate records. Changing vial or liquid settings does not change the published study arm.

How this works

Retatrutide is an investigational single molecule that activates GIP, GLP-1 and glucagon receptors. Human phase 2 trials have examined metabolic outcomes; the indexed schedules describe research arms, not personal-use instructions.

Mechanism summaries are stored with field-level source provenance for editorial audit.

Women in the research

FEMALE REPRESENTATION48.2%163 of 338 participants

DOSE STRUCTURESame study arms across sexesNo separate “women’s dose” was defined.

SEX-SPECIFIC FINDINGSReported as an exploratory subgroupThe publication reported an exploratory difference in mean weight change by sex. It did not define female-specific study arms or a separate dose for women.

Adult enrollment; no female life-stage-specific protocol was defined.

View source